Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
NCT06585787 is registered in ClinicalTrials.gov with Karuna Therapeutics, Inc., a Bristol Myers Squibb company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 26, 2024
- Completion date
- December 22, 2026
- Enrollment
- 406 (estimated)
- Sites
- 296
Conditions
As the registry lists them; a condition with its own page is linked.